M.L. Filipenko – 

Ph.D. (Biol.), Head of Pharmacogenomics Laboratory, Institute of Chemical Biology and Fundamental Medicine,

Siberian Branch of the Russian Academy of Sciences (Novosibirsk)

E-mail: max@niboch.nsc.ru

O.V. Somonova – 

Dr.Sc. (Med.), Professor, N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia (Moscow)

A.L. Elizarova – 

Ph.D. (Biol.), N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia (Moscow)

N.E. Kushlinskii – 

Dr.Sc. (Med.), Professor, Academician RAS, Head of the Laboratory of Clinical Biochemistry N.N. Blokhin 

National Medical Research Center of Oncology of the Ministry of Health of Russia (Moscow)

Venous thromboembolism (VTE) is a common cardiovascular disease that results from a complex interaction between acquired and hereditary factors. A study of the role of the genetic component in recent decades has revealed a number of significant structural genetic variants that increase the risk of developing VET, among which the most studied ones are F5 rs6025, F2 rs1799963, FGG rs2066865, and AB0 blood groups. Genetic loci of predisposition to VET can also increase its likelihood for cancer, which requires careful consideration to assess the possibility of their determination for clinical purposes. Purpose of the study – the current state of studies devoted to the risk formation of venous thromboembolism (VTE) in cancer diseases, taking into account genetic factors.

Search and critically evaluate relevant publications in the PubMed database.

The PubMed database was analyzed using following keywords: “cancer”, “oncological”, “thromboembolism”, “trombosis”, “polymorphism”, “SNP”, “mutation”, “association”. 238 relevant publications were identified and critically evaluated.

Genetic factors make a significant additive contribution to the risk of VTE in patients with cancer, which makes them potential prognostic biomarkers for improving the effectiveness of thromboprophylaxis based on the individual risk of the patient. However, for most well-studied genetic markers of the population risk of VTE, their role in the formation of this type of risk in cancer is characterized as either limited or insufficient, which requires further studies, adequately planned in design and representativeness.

1. Bouillaud S. De l'Obliteration des veines et de son influence sur la formation des hydropisies partielles: consideration sur la hydropisies passive et general // Arch. Gen. Med. 1823. V. 1. P. 188–204.
2. Trousseau A. Phlegmasia Alba Dolens. Clinique Me´dicale de l’Hçtel Dieu de Paris. 2nd edn. V. 3. Paris: JB Baille’re; 1865. P. 659–612.
3. Piazza G. Venous thromboembolism and cancer // Circulation. 2013. V. 128. № 24. P. 2614–2618.
4. Gussoni G., Frasson S., La Regina M., Di Micco P., Monreal M.; RIETE Investigators. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry // Thromb. Res. 2013. V. 131. № 1. P. 24–30.
5. Heit J.A., O’Fallon W.M., Petterson T.M., Lohse C.M., Silverstein M.D., Mohr D.N., Melton L.J. 3rd. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study // Arch. Intern. Med. 2002. V. 162. № 11. P. 1245–1248.
6. Egeberg O. Inherited antithrombin deficiency causing thrombophilia // Thromb. Diath. Haemorrh. 1965. V. 13. P. 516–530.
7. Griffin J.H., Evatt B., Zimmerman T.S., Kleiss A.J., Wideman C. Deficiency of protein C in congenital thrombotic disease // J. Clin. Invest. 1981.  V. 68. № 5. P. 1370–1373.
8. Schwarz H.P., Fischer M., Hopmeier P., Batard M.A., Griffin J.H. Plasma protein S deficiency in familial thrombotic disease // Blood. 1984. V. 64. P. 1297–1300.
9. Bertina R.M., Koeleman B.P., Koster T., Rosendaal F.R., Dirven R.J., de Ronde H., van der Velden P.A., Reitsma P.H. Mutation in blood coagulation factor V associated with resistance to activated protein C // Nature. 1994. V. 369. № 6475. P. 64–67.
10. Middeldorp S., Henkens C.M., Koopman M.M., van Pampus E.C., Hamulyák K., van der Meer J., Prins M.H., Büller H.R. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis // Ann. Intern. Med. 1998. V. 128. № 1. P. 15–20.
11. Rosendaal F.R., Koster T., Vandenbroucke J.P., Reitsma P.H. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance) // Blood. 1995. V. 85. № 6. P. 1504–1508.
12. Blom J.W., Doggen C.J.M., Osanto S., Rosendaal F.R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis // JAMA. 2005. V. 293. № 6. P. 715–722.
13. Pabinger I., Ay C., Dunkler D., Thaler J., Reitter E.M., Marosi C., Zielinski C., Mannhalter C. Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients—results from the Vienna Cancer And Thrombosis Study (CATS) // J. Thromb. Haemost. 2015. V. 13. № 1. P. 17–22.
14. Gran O.V., Smith E.N., Brækkan S.K., Jensvoll H., Solomon T., Hindberg K., Wilsgaard T., Rosendaal F.R., Frazer K.A., Hansen J.B. Joint effects of cancer and variants in the factor 5 gene on the risk of venous thromboembolism // Haematologica. 2016. V. 101. № 9. P. 1046–1053.
15. Heraudeau A., Delluc A., Le Henaff M., Lacut K., Leroyer C., Desrues B., Couturaud F., Tromeur C. Risk of venous thromboembolism in association with factor V leiden in cancer patients – The EDITH case-control study // PLoS One. 2018. V. 13. № 5. e0194973.
16. Poort S.R., Rosendaal F.R., Reitsma P.H., Bertina R.M. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis // Blood. 1996. V. 88. № 10. P. 3698–3703.
17. Kuwahara M., Kurachi S., Kurachi K. Molecular Mechanism of Prothrombin G20210A Variant: Critical New Role of Exon Splicing Enhancer in Poly (A) Tailing // Blood. 2004. V. 104. № 11. P. 1944.
18. Reich L.M., Bower M., Key N.S. Role of the geneticist in testing and counseling for inherited thrombophilia // Genet. Med. 2003. V. 5. № 3.  P. 133–143.
19. Mandalà M., Barni S., Prins M., Labianca R., Tondini C., Russo L., Milesi A., Cremonesi M., Zaccanelli M., Regonesi C., Moro C., Falanga A. Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial // Ann. Oncol. 2010. V. 21. № 4. P. 871–876.
20. Jick H., Slone D., Westerholm B., Inman W.H., Vessey M.P., Shapiro S., Lewis G.P., Worcester J. Venous thromboembolic disease and ABO blood type. A cooperative study // Lancet. 1969. V. 1. № 7594. P. 539–542.
21. Nefzger M.D., Hrubec Z., Chalmers T.C. Venous thromboembolism and blood-group // Lancet. 1969. V. 1. № 7600. P. 887.
22. Lindström S., Brody J.A., Turman C., Germain M., Bartz T.M., Smith E.N., Chen M.H., Puurunen M., Chasman D., Hassler J., Pankratz N., Basu S., Guan W., Gyorgy B., Ibrahim M., Empana J.P., Olaso R., Jackson R., Braekkan S.K., McKnight B., Deleuze J.F., O'Donnell C.J., Jouven X., Frazer K.A., Psaty B.M., Wiggins K.L., Taylor K., Reiner A.P., Heckbert S.R., Kooperberg C., Ridker P., Hansen J.B., Tang W., Johnson A.D., Morange P.E., Trégouët D.A., Kraft P., Smith N.L., Kabrhel C.; INVENT Consortium. A large-scale exome array analysis of venous thromboembolism // Genet. Epidemiol. 2019. V. 43. № 4. P. 449–457.
23. Streiff M.B., Segal J., Grossman S.A., Kickler T.S., Weir E.G. ABO Blood Group Is a Potent Risk Factor for Venous Thromboembolism in Patients with Malignant Gliomas // Cancer. 2004. V. 100. № 8. P. 1717–1723.
24. Li D., Pise M.N., Overman M.J., Liu C., Tang H., Vadhan-Raj S., Abbruzzese J.L. ABO non-O type as a risk factor for thrombosis in patients with pancreatic cancer // Cancer Med. 2015. V. 4. № 11. P. 1651–1658. DOI: 10.1002/cam4.513.
25. Turana D., Yasar H.A., Aksu A.B., Koksoy E.B., Utkanb G., Akbulut H., Urunb U. Risk factors for thrombosis risk in patients with cancer // J. Oncol. Sci. 2018. V. 4, Is. 3. P. 130–133.
26. de Haan H.G., Bezemer I.D., Doggen C.J., Le Cessie S., Reitsma P.H., Arellano A.R., Tong C.H., Devlin J.J., Bare L.A., Rosendaal F.R., Vossen C.Y. Multiple SNP testing improves risk prediction of first venous thrombosis // Blood. 2012. V. 120. № 3. P. 656–663.
27. Tavares V., Pinto R., Assis J., Pereira D., Medeiros R. Venous thromboembolism GWAS reported genetic makeup and the hallmarks of cancer: Linkage to ovarian tumour behaviour // Biochim. Biophys. Acta Rev. Cancer. 2019. V. 1873. № 1. P. 188331.
28. Mosesson M.W., Siebenlist K.R., Meh D.A. The structure and biological features of fibrinogen and fibrin // Ann. NY Acad. Sci. 2001. V. 936.  P. 11–30.
29. Paulsen B., Skille H., Smith E.N., Hveem K., Gabrielsen M.E., Brækkan S.K., Rosendaal F.R., Frazer K.A., Gran O.V., Hansen J.B. Fibrinogen gamma gene rs2066865 and risk of cancer-related venous thromboembolism // Haematologica. 2019. PII: haematol.2019.224279.
30. Rosenthal R.L., Dreskin O.H., Rosenthal N. New hemophilia-like disease caused by deficiency of a third plasma thromboplastin factor // Proc. Soc. Exp. Biol. Med. 1953. V. 82. № 1. P. 171–174.
31. Jarvis K.B., LeBlanc M., Tulstrup M., Nielsen R.L., Albertsen B.K., Gupta R., Huttunen P., Jónsson Ó.G., Rank C.U., Ranta S., Ruud E., Saks K., Trakymiene S.S., Tuckuviene R., Schmiegelow K. Candidate single nucleotide polymorphisms and thromboembolism in acute lymphoblastic leukemia - A NOPHO ALL2008 study // Thromb. Res. 2019. V. 184. P. 92–98.
32. Sundquist K., Wang X., Svensson P.J., Sundquist J., Hedelius A., Larsson Lonn S., Zoller B., Memon A.A. Plasminogen activator inhibitor-1 4G/5G polymorphism, factor V Leiden, prothrombin mutations and the risk of VTE recurrence // Thromb. Haemost. 2015. V. 114. № 6. P. 1156–1164.
33. Falvella F.S., Cremolini C., Miceli R., Nichetti F., Cheli S., Antoniotti C., Infante G., Martinetti A., Marmorino F., Sottotetti E., Berenato R., Caporale M., Colombo A., de Braud F., Di Bartolomeo M., Clementi E., Loupakis F., Pietrantonio F. Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with firstline chemotherapy plus bevacizumab // Pharmacogenomics J. 2017. V. 17. № 4. P. 331–336.
34. Klarin D., Busenkell E., Judy R., Lynch J., Levin M., Haessler J., Aragam K., Chaffin M., Haas M., Lindström S., Assimes T., Huang J., Min Lee K., Shao Q., Huffman J.E., Kabrhel C., Huang Y., Sun Y.V., Vujkovic M., Saleheen D., Miller D.R., Reaven P., DuVall S., Boden W.E., Pyarajan S., Reiner A.P., Trégouët D.A., Henke P., Kooperberg C., Gaziano J.M., Concato J., Rader D., Cho K., Chang K.M., Wilson P.W.F., Smith N.L., O'Donnell C.J., Tsao P.S., Kathiresan S., Obi A., Damrauer S.M., Natarajan P.; INVENT Consortium; Veterans Affairs’ Million Veteran Program. Genomewide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease // Nat. Genet. 2019. V. 51. № 11. P. 1574–1579.
35. Brand J.S., Hedayati E., Humphreys K., Ludvigsson J.F., Johansson A.L., Bergh J., Hall P., Czene K. Chemotherapy, Genetic Susceptibility, and Risk of Venous Thromboembolism in Breast Cancer Patients // Clin. Cancer Res. 2016. V. 22. № 21. P. 5249–5255.
36. Crous-Bou M., Harrington L.B., Kabrhel Ch. Environmental and genetic risk factors associated with venous thromboembolism // Semin. Thromb. Hemost. 2016. V. 42. № 8. P. 808–820.